Dr. Vikram Mathews

Dr. Vikram Mathews
Medical Oncologist, Vellore

MBBS, MD, DM

  • 1 Hospital
  • Dr. Vikram Mathews is a Consultant at Christian Medical College & Hospital, Chennai

Specialities

  • Medical Oncology

Expertise

Education

  • MBBS from Dr.MGR University
  • MD from Dr.MGR University
  • DM from Dr.MGR University
  • Post doctoral fellow from Washington University, St. Louis. USA
  • BoneMarrow Transplant fellowship from Washington University, St. Louis. USA

Practice Information

Christian Medical College & Hospital, Vellore

Christian Medical College & Hospital, Vellore

Ida Scudder Road, Vellore, Tamil Nadu - 632004

Patient Experience

Your participation in the survey will help other patients make informed decisions. You will also be helping Dr. Vikram Mathews and his staff know how they are doing and how they can improve their services.

Achievements & Contributions

  • Acute myeloid leukemia
  • Acute Promyelocytic leukemia
  • Evaluation of mechanisms of resistance to arsenic trioxide and impact of novel agents in the management of acute promyelocytic leukemia
  • Allogeneic stem cell transplant. Improving clinical outcomes by studying risk stratification, modifying conditioning regimens and graft manipulation.
  • Study of inhibitors in hemophilia
  • Investigator award from Bayer Hemophilia Awards program 2006
  • Best abstract and oral presentation award. Asia Pacific BMT meeting. Phuket, Thailand 2010
  • Mathews V, Balasubramanian P, Shaji RV, George B, Chandy M, Srivastava A. Central nervous system relapse in a patient with acute promyelocytic leukaemia treated with arsenic tri-oxide. Br J Haematol. 2001;113:257-258.
  • Mathews V, Chandy M, Srivastava A. Arsenic trioxide in the management of acute promyelocytic leukaemia. Natl Med J India. 2001;14:215-222.
  • Mathews V, Balasubramanian P, Shaji RV, George B, Chandy M, Srivastava A. Arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: a single center experience. Am J Hematol. 2002;70:292-299.
  • George B, Mathews V, Poonkuzhali B, Shaji RV, Srivastava A, Chandy M. Treatment of children with newly diagnosed acute promyelocytic leukemia with arsenic trioxide: a single center experience. Leukemia. 2004;18:1587-1590.
  • Mathews V, Desire S, George B, et al. Hepatotoxicity profile of single agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia, its impact on clinical outcome and the effect of genetic polymorphisms on the incidence of hepatotoxicity. Leukemia. 2006.
  • Mathews V, George B, Lakshmi KM, et al. Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: durable remissions with minimal toxicity. Blood. 2006;107:2627-2632.
  • Mathews V, Thomas M, Srivastava VM, George B, Srivastava A, Chandy M. Impact of FLT3 mutations and secondary cytogenetic changes on the outcome of patients with newly diagnosed acute promyelocytic leukemia treated with a single agent arsenic trioxide regimen. Haematologica. 2007;92:994-995.
  • Thirugnanam R, George B, Chendamarai E, Viswabandya A, Chandy M, Srivastava A, Mathews V. Comparison of clinical outcomes of patients with relapsed acute promyelocytic leukemia induced with arsenic trioxide and consolidated with either an autologous stem cell transplant or an arsenic trioxide-based regimen. Biol Blood Marrow Transplant. 2009;15:1479-1484.
  • Mathews V, George B, Chendamarai E, et al. Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: long-term follow-up data. J Clin Oncol. 2010;28:3866-3871.